Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Receivables - Other (2016 - 2024)

Sangamo Therapeutics (SGMO) has disclosed Receivables - Other for 15 consecutive years, with $4.1 million as the latest value for Q4 2024.

  • For Q4 2024, Receivables - Other rose 917.37% year-over-year to $4.1 million; the TTM value through Dec 2024 reached $4.1 million, up 917.37%, while the annual FY2024 figure was $4.1 million, 917.37% up from the prior year.
  • Receivables - Other hit $4.1 million in Q4 2024 for Sangamo Therapeutics, down from $10.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $10.0 million in Q3 2024 and bottomed at $349000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $2.4 million, with a median of $1.0 million recorded in 2020.
  • Year-over-year, Receivables - Other crashed 84.88% in 2021 and then skyrocketed 917.37% in 2024.
  • Sangamo Therapeutics' Receivables - Other stood at $1.0 million in 2020, then tumbled by 66.28% to $349000.0 in 2021, then surged by 127.51% to $794000.0 in 2022, then crashed by 49.24% to $403000.0 in 2023, then surged by 917.37% to $4.1 million in 2024.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $4.1 million, $10.0 million, and $403000.0 for Q4 2024, Q3 2024, and Q4 2023 respectively.